Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.
Sabine M HermansJuliet A BabiryeOlive MbabaziFrancis KakoozaRobert ColebundersBarbara CastelnuovoChristine Sekaggya-WiltshireRosalind Parkes-RatanshiYukari C ManabePublished in: BMC infectious diseases (2017)
XP usage was lower than expected. The lower sensitivity of XP in smear-negative HIV-positive patients led experienced clinicians to use XP as a "rule-in" rather than "rule-out" test, with the majority of patients still treated empirically.
Keyphrases
- hiv positive
- end stage renal disease
- men who have sex with men
- newly diagnosed
- pulmonary tuberculosis
- antiretroviral therapy
- south africa
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- type diabetes
- human immunodeficiency virus
- cardiovascular disease
- patient reported outcomes
- coronary artery disease
- hiv infected
- replacement therapy